PMN Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$116,448.79
Insider Selling (Last 12 Months): C$0.00

ProMIS Neurosciences Insider Trading History Chart

This chart shows the insider buying and selling history at ProMIS Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ProMIS Neurosciences Share Price & Price History

Current Price: C$7.70
Price Change: +0.30 (1.20%)
As of 12/5/2022 01:00 AM ET

This chart shows the closing price history over time for PMN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

ProMIS Neurosciences Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2022Patrick D. KirwinDirectorBuy4,000C$7.65C$30,600.0041,982
7/11/2022Eugene Warren WilliamsDirectorBuy1,000C$9.80C$9,800.00155,764
6/30/2022Eugene Warren WilliamsDirectorBuy200C$8.31C$1,662.63152,764
6/30/2022Neil CashmanSenior OfficerBuy609C$8.19C$4,984.67102,661
6/27/2022Eugene Warren WilliamsDirectorBuy5,000C$0.14C$689.008,858,816
6/23/2022Eugene Warren WilliamsDirectorBuy500,000C$0.13C$64,285.008,503,816
6/23/2022Neil CashmanSenior OfficerBuy38,500C$0.12C$4,427.506,069,144
12/3/2021Patrick D. KirwinDirectorSell31,500C$0.15C$4,567.501,641,450
See Full Table

SEC Filings (Institutional Ownership Changes) for ProMIS Neurosciences (TSE:PMN)

ProMIS Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More on ProMIS Neurosciences

Today's Range

Now: C$7.70
Low: C$7.70
High: C$7.80

50 Day Range

MA: C$8.07
Low: C$6.90
High: C$8.98

52 Week Range

Now: C$7.70
Low: C$5.70
High: C$12.22


1,147 shs

Average Volume

3,287 shs

Market Capitalization

C$66.06 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of ProMIS Neurosciences?

ProMIS Neurosciences' top insider shareholders include:
  1. Eugene Warren Williams (Director)
  2. Neil Cashman (Senior Officer)
  3. Patrick D Kirwin (Director)
Learn More about top insider investors at ProMIS Neurosciences.
The "NEW" Oil and Gas Crisis: Lack Of Lithium
We are in a global lithium crisis that's going to get far worse. Just like OPEC and Russia control the price and supply of oil and gas, China has the U.S. in a chokehold when it comes to lithium.
Click here to see how the prices may explode